Should women over 75 still get mammograms? What each guideline says

The question has an unusual shape: four expert bodies, four slightly different answers, and no outright disagreement about the evidence. Three of them tie the decision past 75 to the woman's health and how long she is likely to live; the USPSTF leaves it to clinical judgment. They differ on what the default should be while that conversation happens.

Read across the rows, the pattern is that age 75 is a checkpoint rather than an endpoint. Only the USPSTF declines to set a default, and it does so because of a gap in the evidence, not because it found harm.

An I statement is the Task Force saying it cannot tell. It is not a D grade, which is how the Task Force recommends against a service. Its clinician summary puts the consequence in plain terms: "There is insufficient evidence to recommend for or against screening for breast cancer in women 75 years or older," and "Clinicians should use their clinical judgment regarding whether to screen for breast cancer in women 75 years or older."

The reason is stated in the same document. Breast cancer incidence "peaks among persons aged 70 to 74 years, although rates in persons 75 years or older remain high," yet "no randomized clinical trials (RCTs) of breast cancer screening included women 75 years or older." Two indirect lines of evidence then point in different directions: the Task Force's commissioned modeling "suggests that screening in women 75 years or older is of benefit, but a trial emulation found no benefit with breast cancer screening in women aged 75 to 84 years."

This is not new. The 2016 statement reached the same I finding for 75 and older. The 2024 update moved the routine starting age from 50 to 40 and left the upper end exactly where it was. During public comment on the 2024 draft, several commenters asked for no upper age limit or for one based on life expectancy; the Task Force answered that no trial had enrolled women 75 or older and that the emulated trial "showed no benefit to screening women aged 75 to 79 or 80 to 84."

The trial emulation the Task Force leans on is a 2020 analysis in the Annals of Internal Medicine by García-Albéniz and colleagues. It used Medicare data from 2000 to 2008 on 1,058,013 women aged 70 to 84 who had a life expectancy of at least 10 years, no previous breast cancer, and a screening mammogram, and compared two strategies: keep having annual mammograms, or stop. Its own abstract notes that "no trials have studied whether or when women can safely stop screening mammography," which is the gap it set out to fill with observational data.

In women 70 to 74 the estimate leaned toward a benefit from continuing. From 75 to 84 the hazard ratio sat at 1.00: no measurable difference in breast cancer deaths over eight years. The authors' conclusion is that continuing annual screening past 75 "did not result in substantial reductions in 8-year breast cancer mortality compared with stopping screening."

Continuing did find more cancers. As the USPSTF summarizes the study, the 8-year cumulative risk of a breast cancer diagnosis was 5.8 percent in women 75 to 84 who kept screening against 3.9 percent in those who stopped, and the extra diagnoses "did not contribute to a difference in the risk of breast cancer mortality, likely due to competing causes of death, raising the possibility that the additionally diagnosed cancers represent overdiagnosis." Overdiagnosis means finding a cancer that would never have caused harm in the woman's lifetime, and the USPSTF lists overtreatment of such cancers among the harms of screening.

ACOG's Practice Bulletin 179 lays out the reasoning most fully. It grades "continue screening mammography until at least age 75 years" as a Level A recommendation, its highest. For the years beyond, it uses its consensus tier, Level C: "Age alone should not be the basis to continue or discontinue screening."

The bulletin explains why age is a poor proxy. "Many women 75 years and older are in good health and can be expected to live considerably longer than 10 years, and more than one half of women older than 80 years are expected to live more than 10 years." The other side of the same arithmetic: "Women with a life expectancy of less than 10 years are unlikely to have an appreciable mortality reduction from mammographic detection of an early breast cancer and are at a substantial risk of discomfort, anxiety, and decreased quality of life from adverse effects of treatment that is unlikely to extend their life."

ACOG also names how clinicians make the estimate: "Clinical judgment and predictive models that combine age, comorbidities, and functional status can be used to identify women who may continue to benefit from screening mammography (generally defined as having greater than a 50% probability of surviving 10 years)." And it adds one condition that applies at any age: "screening mammography should not be performed on women who would not choose further evaluation or treatment based on abnormal screening results."

ACS draws the same 10-year line in a single sentence. ACR and the Society of Breast Imaging draw it more loosely, setting no upper age "unless severe comorbidities limit life expectancy," and frame the choice from the benefit side: "Women who wish to maximize benefit will choose annual screening starting at age 40 years and will not stop screening prematurely." The difference between them is mostly where the default sits for a healthy 78-year-old, not whether her health matters.

Medicare's rule is mechanical and has no ceiling. Medicare.gov lists screening mammograms for women 40 or older, once every 12 months, and says you pay nothing for the test if the provider accepts assignment. The underlying regulation, 42 CFR 410.34, sets lower age limits and, for "an asymptomatic woman over 39 years of age," requires at least 11 months after the month of the last screening mammogram. It sets no upper age.

That makes the cost question simple and leaves the medical one untouched. Medicare paying for a yearly mammogram at 82 is a coverage fact. It is not a guideline, and none of the four bodies above treats it as one.

All four positions are written for women at average risk. The USPSTF's statement applies to women with a family history of breast cancer or dense breasts, and expressly does not apply to anyone with "a genetic marker or syndrome associated with a high risk of breast cancer (eg, BRCA1 or BRCA2 genetic variation), a history of high-dose radiation therapy to the chest at a young age, or previous breast cancer or a high-risk breast lesion on previous biopsies." If one of those applies to you, the over-75 positions above were not written for your situation. And screening is for women with no symptoms: ACS advises that any change in how the breasts look or feel should be reported to a healthcare provider right away, at any age, which is a diagnostic visit rather than a screening decision.

Our breast cancer screening page sets out all four bodies' positions from age 40 onward, each quoted and dated at the row level, including the interval disagreement this guide does not cover. Your personal screening plan lists the screenings that apply at your age and sex, so the mammogram question can be raised alongside the rest at one visit.

The same question about stopping comes up for men, with a sharper answer: the USPSTF's 2018 statement, now being updated, grades PSA screening at 70 and older a D, a recommendation against, which we cover in normal PSA levels by age. For routine blood work, which follows different rules again, see the blood tests worth getting every year.

The decision itself is made with a clinician who knows your health. The questions ACOG's reasoning points to are useful ones to bring: how my current health affects my outlook over the next 10 years, and whether I would want further tests or treatment if a small cancer were found.